Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta® (lefamulin), approved by the FDA in 2019 for both Oral and IV use, and CONTEPO (fosfomycin) for injection. The approval of CONTEPO has been impacted by FDA’s travel restrictions due to COVID-19. We have engaged with the FDA to determine next steps for CONTEPO. In July 2020, Nabriva Therapeutics entered into an exclusive agreement with Merck & Co. Inc., to promote and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and adolescent patients for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and Fort Washington, PA.
Events & Presentations
Monday September 13, 2021 7:00 AM EDT
H.C. Wainwright 23rd Annual Global Investment Conference
Thursday August 5, 2021 4:30 PM EDT
Nabriva Therapeutics Second Quarter 2021 Financial Results Call
Thursday June 3, 2021 2:30 PM EDT
Jefferies Virtual Healthcare Conference
|Filing date||Description||Form||Filing Group||View|
Report of unscheduled material events or corporate event
|EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA|
Statement of changes in beneficial ownership of securities
Initial filing by director officer or owner of more than ten percent.